The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.
The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, with a compound annual growth rate (CAGR) of 4.0%, according to "Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration," a new analysis by Informa's Meddevicetracker.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
